When cravings stop working

It begins with silence. Again and again, GLP-1 users describe the same revelation: the food noise simply disappears. The constant negotiation around what to eat, when to eat and how much to resist goes quiet. For people who have spent years fighting their own appetite, that quiet is not a side effect. It is the point.

And it is the first clue that GLP-1s are not just changing weight. They are changing what people want - and, in doing so, rewiring consumption itself.

MMR’s research with 3,000 people across the UK, US, Germany, Brazil and China captures a story that is still unfolding, but whose direction is becoming harder to ignore. Among British users, 83% say they feel more in control of their eating and drinking. Across current and past users, 51% say GLP-1s reduced constant, unwanted thoughts about food.

The most consequential health innovation of the decade is not only changing how much people weigh – it’s also changing what they want.

Most of the industry has read GLP-1s as a volume threat: smaller baskets, fewer snacks, less alcohol, weaker impulse purchasing. All of that may be true. It is also the least interesting thing happening. They do not merely ask consumers to exercise more willpower. For many, they change the intensity of the wanting itself.

Seen this way, GLP-1s begin to look less like weight-loss products and more like behavioural technologies: clinical interventions capable of reshaping the relationship between appetite, reward and choice. Food and drink companies have spent decades engineering desire. What happens when desire is no longer enough to guarantee selection?

It would be a mistake to romanticize that control. Eighty-two percent of current and past users in our study said they had felt stuck in their attempts to manage their weight before starting GLP-1s. Relief arrives, but it often arrives inside an unfamiliar body.

Side effects can make appetite unpredictable rather than simply smaller. Sweetness may become overwhelming. Rich dishes can feel heavy. Old favorites lose their pull, while previously ordinary tastes can become more intense. Some users carefully manage portions because overeating now brings swift discomfort; others retreat to ‘safe foods’ that feel tolerable, emotionally as well as physically.

What emerges is not a tidier diet. It is the reconstruction of everyday life under a new biological reality: learning how to shop, socialize, celebrate and indulge in a body that behaves differently.

This does not mean the end of pleasure, but it may mean the end of low-value reward.

Users do not necessarily stop treating themselves. They may do it less frequently, in smaller quantities and with much higher expectations of the experience. One square of chocolate can still be satisfying. A full dinner may feel impossible. Appetite state begins to matter as much as the occasion, and indulgence has to coexist with reassurance, digestibility, nutrient density and control.

That changes the innovation brief. The brands that succeed will make every mouthful matter more. They will create denser pleasure: products that earn their place through flavour, texture, ritual, discovery or emotional meaning - not just through their ability to trigger another craving.

In other words, the future of food may be defined less by temptation and more by intention.

The commercial implications do not stop with people taking the medication. As portions shrink, high-protein choices normalize and controlled consumption becomes culturally visible, expectations can migrate. Non-users begin to absorb the same language of satiety, selectivity and restraint. What begins as a pharmaceutical intervention can become a new social norm.

Nor do the consequences stop at the table. They spill into beauty and wellness, social occasions and the everyday definition of what a good product is supposed to do.

This is why GLP-1s should not be treated as a niche segment requiring a niche range. The deeper challenge is to design products that work brilliantly for people whose relationship with appetite has changed, while remaining desirable to everyone else. The opportunity is not ‘food for patients’. It is better-calibrated food for a culture becoming more considered.

There is one more consumer the industry is barely designing for: the person who stops.

Cost, side effects and the difficulty of sustaining treatment mean that discontinuation is part of the current experience. When medication ends, hunger can return faster than confidence. Old routines, cravings and food noise reappear, while the sense of control people fought hard to gain begins to wobble.

The post-GLP-1 consumer is not simply chasing fullness. They are looking for stability: food that feels safe without feeling joyless; pleasure without surrender; support without judgement. The biggest commercial opportunity may not sit inside weight loss at all, but in helping people protect what they gained after it.

Which leaves CPG with an uncomfortable, era-defining question: if appetite is no longer the engine of consumption, can your products still earn a place in people’s lives?

MMR combines evidence, experience and expertise to help brands turn the disruption of GLP‑1s into clearer decisions, stronger innovation and better product experiences. If you’re looking for a trusted global research partner for what comes next, let’s talk.